Analysts Offer Predictions for Novartis AG’s Q1 2025 Earnings (NYSE:NVS)

Novartis AG (NYSE:NVS) – Zacks Research upped their Q1 2025 earnings per share (EPS) estimates for shares of Novartis in a research report issued on Monday, September 30th. Zacks Research analyst E. Bagri now anticipates that the company will post earnings per share of $1.93 for the quarter, up from their previous forecast of $1.92. The consensus estimate for Novartis’ current full-year earnings is $7.50 per share. Zacks Research also issued estimates for Novartis’ Q3 2025 earnings at $2.20 EPS and FY2025 earnings at $8.26 EPS.

Several other equities research analysts have also commented on the company. The Goldman Sachs Group restated a “neutral” rating and set a $121.00 price target (up from $119.00) on shares of Novartis in a research note on Thursday, September 5th. Barclays raised shares of Novartis to a “strong sell” rating in a research report on Monday, June 24th. Jefferies Financial Group cut shares of Novartis from a “buy” rating to a “hold” rating in a research report on Tuesday, September 3rd. Bank of America lowered shares of Novartis from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $135.00 to $130.00 in a research report on Wednesday, September 11th. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Novartis in a research note on Friday, July 19th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $120.70.

Novartis Trading Down 0.4 %

Shares of Novartis stock opened at $114.53 on Wednesday. Novartis has a fifty-two week low of $92.19 and a fifty-two week high of $120.92. The business’s fifty day moving average is $115.17 and its two-hundred day moving average is $106.30. The company has a quick ratio of 0.72, a current ratio of 0.93 and a debt-to-equity ratio of 0.47. The firm has a market cap of $234.10 billion, a PE ratio of 15.46, a P/E/G ratio of 1.73 and a beta of 0.57.

Novartis (NYSE:NVS) last announced its earnings results on Thursday, July 18th. The company reported $1.97 EPS for the quarter, beating analysts’ consensus estimates of $1.87 by $0.10. The firm had revenue of $12.87 billion for the quarter, compared to analysts’ expectations of $12.24 billion. Novartis had a return on equity of 34.56% and a net margin of 33.76%. During the same quarter in the prior year, the firm earned $1.83 EPS.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in NVS. TD Asset Management Inc increased its holdings in shares of Novartis by 314.8% in the fourth quarter. TD Asset Management Inc now owns 55,096 shares of the company’s stock valued at $5,563,000 after buying an additional 41,815 shares in the last quarter. CWA Asset Management Group LLC acquired a new position in shares of Novartis in the 4th quarter valued at $811,000. CIBC Private Wealth Group LLC lifted its stake in Novartis by 29.0% during the fourth quarter. CIBC Private Wealth Group LLC now owns 625,605 shares of the company’s stock valued at $63,160,000 after buying an additional 140,561 shares in the last quarter. First Trust Advisors LP raised its holdings in shares of Novartis by 1.2% during the fourth quarter. First Trust Advisors LP now owns 678,674 shares of the company’s stock valued at $68,526,000 after acquiring an additional 7,870 shares during the period. Finally, Lake Street Advisors Group LLC acquired a new position in Novartis in the 4th quarter worth approximately $738,000. Institutional investors and hedge funds own 13.12% of the company’s stock.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.